Retrospective Descriptive Study of a Cohort of Non-HIV Immunocompromised Patients With Toxoplasmosis at the Strasbourg University Hospital From 2010 to 2023
Toxoplasmosis in HIV-positive individuals is well-studied and has a codified management protocol, which is not the case for other immunodeficiencies, except for recent recommendations in the context of hematopoietic stem cell transplantation. A description of this population is necessary to estimate the number of patients affected and to define their specific management (diagnosis, treatment, prevention).
• Adult (≥18 years)
• Immunocompromised (i.e., solid organ transplant recipient, hematological malignancy, cancer patient, patient treated with immunosuppressive therapy or therapy affecting the immune system by any mechanism, hematopoietic stem cell transplant recipient, patient with an autoimmune disease or immunodeficiency, whether primary or secondary).
• At least one positive toxoplasmosis PCR test (regardless of tissue)